IMMUNOTHERAPY IN PEDIATRIC MALIGNANCIES: OPPORTUNITIES AND ISSUES

SYMPOSIUM IS ORGANISED AND SUPPORTED BY



Wednesday, October 23rd | 12:00 - 13:30 | Forum 6

Chairs: Prof. Gilles Vassal, France & Prof. François Doz, France & Prof. Jean-Yves Blay, France

12:00–12:35	Emerging use of car-t cells in leukemia and solid tumors Prof. Andrea Biondi, (Italy)
12:35–12:55	The role of checkpoint inhibitors in hypermutated tumors Prof. Eric Bouffet, (Canada)
12:55–13:15	The role of checkpoint inhibitors in solid tumors and lymphomas Dr. Véronique Minard-Colin, (France)
13:15–13:30	Audience guestions and discussion

THE TREATMENT OF PEDIATRIC AND AYA PATIENTS WITH ALL: INSIGHTS ON BEST PRACTICE

SYMPOSIUM IS ORGANISED AND SUPPORTED BY



Wednesday, October 23rd | 17:30 - 18:30 | Forum 6

Chair: Dr. Martin Schrappe, FRCP, (Germany)

17:30–17:35 **Welcome and introduction** Martin Schrappe, (Germany)

17:35–17:50 Current protocols for pediatric and aya patients with all: a review the evidence

Valentino, Conter, (Italy)

17:50–18:05	Putting the Evidence Into Best Practice: Insights From an Expert Center Kjeld Schmiegelow, (Denmark)
18:05–18:25	The Pediatric and AYA ALL Case Clinic: Expert Insights on Best Practice Scott Howard, (United States)
18:25-18:30	Summary and close Martin Schrappe, (Germany)

TARGETED TREATMENT IN PAEDIATRIC ONCOLOGY: MANAGEMENT OF TRK FUSION CANCER

SYMPOSIUM IS ORGANISED AND SUPPORTED BY



Thursday, October 24 | 07:30 - 08:30 | Forum 6

Chair: Professor Gilles Vassal (France)

07:30–07:35	Welcome and introduction Professor Gilles Vassal, (France)
07:35-07:50	NTRK gene fusions in paediatric tumours: Testing and molecular profiling Professor Stefan Pfister, (Germany)
07:50-08:05	NTRK gene fusions as actionable targets Professor Gilles Vassal, (France)
08:05-08:20	Interactive case session Professor Gilles Vassal, (France), Professor Stefan Pfister, (Germany)
08:20-08:30	Q&A and meeting close

Professor Gilles Vassal, (France), Professor Stefan Pfister, (Germany)

EVOLUTION OF ASPARAGINASE THERAPY AND TDM IN ACUTE LYMPHOBLASTIC LEUKAEMIA

THIS PROMOTIONAL SYMPOSIUM IS ORGANISED AND SUPPORTED BY



Thursday, 24th October | 12:00 - 13:30 | Forum 6

Chair: Prof Yves Bertrand (France)

12:00–12:10 **Introduction**

Prof Yves Bertrand, (France)

12:10–12:30 The evolution of asparaginase in paediatric (all) protocols

Kjeld Schmiegelow (Denmark)

12:30–13:15 Perspectives on asparaginase therapeutic drug monitoring (tdm):

Experiences of TDM in AIEOP-BFM ALL protocols with a focus on the 2009 and 2017 trials

Prof Carmelo Rizzari, (Italy)

Experiences of TDM in DCOG ALL-10 and DCOG ALL-11 protocols and a focus on the ALL together protocol

Prof Rob Pieters, (Netherlands)

13:15–13:30 Audience q&a and conclusions

Prof Yves Bertrand, (France)

This is a promotional meeting organised and funded by Jazz Pharmaceuticals PI is available at the symposium.

Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse events via their national reporting system. In the United Kingdom: Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ Adverse events should also be reported to Jazz Pharmaceuticals at AEreporting@jazzpharma.com or by fax to +44 (0) 1865 598765

Date of preparation: August 2019; Code: EURW-INTERW-0043a

PERSONALISED HEALTHCARE IN PAEDIATRIC ONCOLOGY – TAKING THE NEXT STEP

SYMPOSIUM IS ORGANISED AND SUPPORTED BY



Friday, 25 October 2019 | 12:50 – 14:20 | Auditorium Lumiere

Chair: Dr Gilles Vassal (France)

12:50-13:00	Welcome and Introduction Dr Gilles Vassal (France)
13:00-13:10	Drug Development for Paediatric Patients with Cancer Dr Hubert Caron (Roche Switzerland)
13:10-13:25	Comprehensive Genomic Profiling To Guide Treatment Decisions Natacha Entz- Werle (France)
13:25-13:45	Moving Towards Precision Medicine in Paediatrics – Making INFORMed Choices Stefan Pfister (Germany)
13:40-14:05	A Personalised Healthcare Treatment Example: Experience with NTRK Inhibitors in Paediatric Patients Dr Amar Gajjar (USA)
14:00-14:20	Panel Discussion / Q&A Chair / all

NEUROBLASTOMA CHALLENGES: MANAGING HIGH-RISK AND RELAPSED/REFRACTORY DISEASE TODAY AND TOMORROW

SYMPOSIUM IS ORGANISED AND SUPPORTED BY



Friday, October 25th| 12:50 - 14:20 | Forum 6

Chair: Dr Dominique Valteau-Couanet (France)

Chair. Bi Bollinique Valeau-Oddanet (France)		
12:50–12:55	Welcome and Introduction Dr Dominique Valteau-Couanet, (France)	
12:55–13:15	Newly diagnosed high-risk neuroblastoma: latest research Dr Ruth Ladenstein, (Austria)	
13:15–13:35	High-risk relapsed/refractory neuroblastoma: latest research Dr Holger Lode, (Germany)	
13:35–13:50	High-risk neuroblastoma management today: practical considerations Dr Claudia Pasqualini, (France)	
13:50–14:05	High-risk neuroblastoma tomorrow: what might the future hold? Dr Giuseppe Barone, (UK)	
14:05–14:20	Panel Discussion and Q&A All, facilitated by Dr Dominique Valteau-Couanet, (France)	

HOW TO INTEGRATE THE MEVION COMPACT PROTON THERAPY SOLUTION IN YOUR DEPARTMENT

PRODUCT THEATER IS ORGANISED AND SUPPORTED BY



Thursday, October 24, 2019 | 09:15 - 09:35 AM | Product Theater Exhibit Hall

Speaker: Vincent Tallier (Belgium)

Speaker's Title: Director, Strategic Partnerships EMEA

QUALITY OF LIFE STUDY IN CHILDREN DEVELOPING OTOTOXICITY

PRODUCT THEATER IS ORGANISED AND SUPPORTED BY



Thursday, October 24, 2019 | 15:50 – 16:10 | Product Theater Exhibit Hall

15:50–15:55 **Introduction**

Dr. James Geller, (USA) Professor of Pediatrics

Medical Director, Kidney and Liver Tumor Programs Director, Advanced Cancer Therapeutics Network

Director, Pilot Translational and Clinical Studies Program, CCTST

Cincinnati Children's Hospital Medical Center

Division of Oncology

15:55–16:10 Quality of life issues in children developing ototoxicity

Dr. Kaukab Rajput (United Kingdom) Consultant Audiological Physician & Lead Physician for Paediatric Cochlear Implant Program Great Ormond Street Hospital NHS Foundation Trust London, UK